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Autologous stem cell transplant (ASCT) is the standard of care in transplant-eligible multiple myeloma patients and is associated
with significant improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS).However,
majority of patients eventually relapse, with a median PFS of around 36months. Relapses are harder to treat and prognosis declines
with each relapse. Achieving and maintaining “best response” to initial therapy is the ultimate goal of first-line treatment and
sustained CR is a powerful surrogate for extended survival especially in high-risk multiple myeloma. ASCT is often followed by
consolidation/maintenance phase to deepen and/or maintain the response achieved by induction and ASCT. Novel agents like
thalidomide, lenalidomide, and bortezomib have been used as single agents or in combination.Thalidomide use has been associated
with a meaningful improvement in PFS and EFS, however, with substantial side effects. Data with lenalidomide maintenance after-
ASCT is favorable, but the optimal duration of lenalidomide maintenance is still unclear. Bortezomib use has been associated with
superior outcomes, predominantly in high-risk myeloma patients. Combination regimens utilizing a proteasome inhibitor (i.e.,
bortezomib) with an immunomodulatory drug (thalidomide or lenalidomide) have provided the best outcomes.This review article
serves as a review of the best available evidence in post-ASCT approaches in multiple myeloma.
1. Introduction
Autologous stem cell transplant (ASCT) is the standard of
care in transplant-eligible patients, based on several phase
III trials and meta-analyses in the mid-1990s showing sig-
nificant improvement in progression-free survival (PFS) and
complete remission rates (CR) as well as overall survival (OS)
[1–3]. In their IFM-90 trial, Attal et al. reported superior
outcomes of high-dose chemotherapy (HDC) followed by
ASCT compared to conventional chemotherapy alone, with
improvement noted in OS (57%), complete remission rate
CR (22%) and event-free survival EFS (16%), as well as
median OS improvement to 57 months versus 44 months
[1]. However, majority of patients eventually relapsed with
a median PFS of around 36 months. Unfortunately, relapses
are harder to treat and prognosis declines with each relapse.
Therefore, achieving and maintaining “best response” to
initial therapy is the ultimate goal of first-line treatment.
Several studies have shown that sustained CR for 3 years or
more from treatment initiation is a powerful surrogate for
extended survival especially in high-risk multiple myeloma
[4].
The treatment algorithm for newly diagnosed multiple
myeloma (MM) has evolved over the last two decades with
the incorporation of novel agents in myeloma induction
regimens prior to ASCT [5, 6]. Improved outcomes when
used before ASCT were the basis for the use of these agents
in the post-ASCT setting as a means to deepen and maintain
the response achieved by HDC-ASCT in myeloma patients.
The benefit of maintenance therapy is thought to be due to
suppression of clonal proliferation of myeloma cancer cells
thereby delaying or preventing relapse.
In this review article, we will briefly review the signifi-
cance of the depth of response to induction chemotherapy
and will focus on how to deepen or maintain response by
means of a consolidation approach, maintenance, or both.
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Figure 1: Achievement of CR is associated with improvement in survival outcomes after induction as well as after ASCT (adapted with
permission from [10]).
2. Significance of Depth of Response to
Chemotherapy
Multiple studies have suggested a survival advantage from
attaining a deeper response to induction chemotherapy and
HDC-ASCT, and sustained CR was shown to be a surrogate
for OS in myeloma population [7–14] (see Figure 1). In a
meta-analysis of 21 studies including 4,990 patients in 10
prospective and 11 retrospective studies, highly significant
associations between maximal response and survival out-
comes were demonstrated [7]. However, it remains uncertain
whether this just reflects underlying disease biology (i.e.,
prognostic marker) versus a specific treatment effect, espe-
cially since the definition of CR was historically ununified
until the development of the IMWG treatment response
criteria [8, 9].
Furthermore, achieving stringent CR (sCR), as defined
by IMWG criteria, is associated with even better outcomes
compared to CR, with median time-to-progression of 50
months with sCR versus 20 months with CR [11, 12]. The
benefit is more pronounced when comparing OS outcomes
(see Figure 2).
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Figure 2: sCR is associated with superior PFS and OS compared to CR (adapted from [11]).
2.1. Evaluation of Minimal Residual Disease (MRD). The
techniques for assessing disease burden in MM have evolved
over time. Sensitive methods to detect MRD have been used
to evaluate either immunophenotypic response or molecular
response [13, 14, 18, 19]. In their recent article about Contro-
versies in the Assessment of Minimal Residual Disease in MM,
Corradini et al. reviewed the clinical significance of MRD
negativity using highly sensitive techniques and concluded
that, at the present time, the goal of assessing MRD is for
risk stratification and to evaluate response to novel agents
particularly in the context of clinical trials [20].
Immunophenotypic response assessment bymultiparam-
eter flow cytometry (MFC) was evaluated after ASCT in a
subset of patients enrolled in Myeloma Research Council
(MRC) IX, the Spanish GEM 2000, and GEM 2005 trials.
Absence of MRD at D + 100 was associated with statistically
significant improvement in both PFS and OS in patients with
favorable and adverse cytogenetics [13, 21, 22]. Additionally,
persistent MRD by MFC at D + 100 (HR 8.0, 𝑃 = 0.005) and
high-risk cytogenetics by FISH (HR 17.3, 𝑃 = 0.002) were the
only independent factors that predicted unsustained CR and
shortened OS [22].
Molecular response can be assessed by either PCR-based
techniques (either fluorescent or allele-specific oligonu-
cleotide PCR) or next generation sequencing (NGS). MRD
assessment by PCR was evaluated in several trials and
homogenously showed that lower levels of MRD were asso-
ciated with markedly better survival and longer disease-free
periods [14, 23–25].
It should be noted, though, that these results were based
on subsets of patients enrolled in the cited trials where
MRD assessment was done only in those who had a bone
marrow sample at D + 100 (in those assessed by MFC),
thus raising concern for selection bias. Additionally, variety
of technical factors can affect the sensitivity, specificity, and
applicability of MFC such as time of sampling with respect
to treatment, number of markers, number of cells counted,
and marrow cellularity. On the other hand, PCR and NGS,
despite being very sensitive forMRDdetection, are limited by
the technical complexity and the lack of validated threshold
to separate high from lowMRD to better allow establishment
of prognostic variables [21–26].
In conclusion, all methods reliably differentiated between
MRD-positive versus -negative cases and successfully corre-
latedMRDnegativity with improved outcomes.MFC appears
to have the greatest applicability, whereas PCR and NGS
demonstrated higher sensitivity. Other techniques for MRD
assessment such as detection of circulating tumor cells and
whole-body PET-CT/MRI seem to have potential to add
sensitivity for MRD detection, especially in extramedullary
disease and/or oligo- or nonsecretory MM [26]. However,
these approaches are still investigational and need further
validation in the context of clinical trials.
3. Consolidation and Maintenance
Strategies in MM
Despite the remarkable improvement in the outcome of
MM treatment over the last two decades with the use
of immunomodulatory and novel agents, MM remains an
incurable disease. Multiple studies over the last few years
have examined the role of maintenance, consolidation, or
both to eliminate residual disease after HDC-ASCT in MM.
Consolidation is typically a short course, more intensive,
with the main goal of deepening the response achieved
by induction chemotherapy and HDC-ASCT. Maintenance
is given for a prolonged period of time with the goal of
preventing/delaying disease progression. Both approaches
showed favorable outcomes in terms of delaying relapse and
need for second line intensive therapy. However, it remains
unclear whether there is a significant survival advantage to
justify the cost and toxicity of continued treatment. The
ideal regimen should be easy to deliver, convenient to use,
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cost-effective, havemodest toxicity and lead to improved PFS
and ideally OS over retreatment at relapse [27, 28].
Historically, interferons (IFN) and glucocorticoids were
the first agents studied in themaintenance setting after induc-
tion. Berenson et al. compared alternate-day oral prednisone
at 2-dose levels (10mg versus 50mg) in a subset of patients
achieving at least 25% tumor reduction following induction
therapy during their enrollment in SWOG 9210 trial (𝑛 =
125). Significant improvements were noted in both PFS (14
versus 5 months, 𝑃 = 0.003) and OS (37 versus 26 months,
𝑃 = 0.05) favoring those receiving the 50mg dose [29].
4. Post-ASCT Strategies in MM
Multiple studies have examined the role of consolidation
and/or maintenance following HDC-ASCT to eliminate
residual disease in MM. IFN-𝛼 was evaluated in 2 major
studies and showed improved PFS, however, with substantial
side effects and no survival benefit [30, 31]. Glucocorticoids
were compared to IFNs and produced similar remission rates,
but reinduction at relapse was more successful in those who
received post-ASCT IFN [32].
4.1. Thalidomide Use after ASCT. Several randomized trials
evaluated the use of thalidomide after ASCT [15, 16, 33–
38] (see Table 1). Thalidomide’s use has been associated with
a meaningful improvement in PFS (by approximately 10
months) and EFS.However, the efficacy of thalidomidemain-
tenance was counterbalanced by the significant rate of both
acute and long-term side effects leading to discontinuation of
the drug in a substantial number of patients ranging between
30–80% by 2 years in different studies [15, 16, 33–35, 37–45].
Due to increased toxicity of maintenance thalidomide,
significant improvement in overall survival outcomeswas not
observed.
In their 2012 meta-analysis, IMWG reviewed 6 random-
ized trials with a total of 2786 patients evaluating thalidomide
use after HDC-ASCT in myeloma [46]. Thalidomide main-
tenance was associated with significant improvement in PFS
(HR 0.65; 95% CI 0.59–0.72) and OS (HR 0.84; 95% CI 0.73–
0.97); however, there was considerable heterogeneity among
individual trials, likely due to variability in inclusion criteria
and salvage treatment of choice at disease progression/relapse
(see Figures 3 and 4).
In conclusion, thalidomide use after ASCT appeared to
have appeared to be most beneficial in MM with standard-
risk disease. It may be more efficacious when combined
with a proteasome inhibitor or glucocorticoids, as discussed
below [9]. However, in considering such an approach, one
should be vigilant about the risk/benefit ratio in individual
patients taking into account their comorbidities and residual
toxicities from previous treatment, given the considerable
discontinuation rate secondary to toxicity noted in different
studies.
4.2. Lenalidomide Use after ASCT. Twomajor phase III trials
evaluated the role of lenalidomide use after HDC-ASCT in
MM and showed improvement in PFS and TTP [47–49]. In
the IFM2005-02 trial, Attal et al. evaluated lenalidomide after
ASCT in 614 patientswhere all study subjects received 2 cycles
of lenalidomide consolidation and then got randomized
to either lenalidomide maintenance arm (10mg/day for 3
months and then 15mg/day) or placebo until disease pro-
gression, intolerable side effects, or death [47]. However, at
a median of 32 months, maintenance was discontinued when
an interim analysis showed increased risk of second primary
malignancies (SPMs) with lenalidomide maintenance. At a
median follow-up of 45 months, lenalidomide maintenance
was associated with improvement in median PFS (41 months
versus 23 months in the placebo arm, HR 0.50, 𝑃 < 0.001).
However,OS rate at 5 years fromdiagnosiswas similar in both
arms.
In comparison, CALGB-100104 trial that evaluated
lenalidomide maintenance after ASCT did not include a
consolidation phase and it permitted crossover [48]. 460
patients were randomized, after achieving at least stable
disease after ASCT, to either lenalidomide maintenance
(10mg/day for 3months and then 15mg/day) or placebo until
disease progression, intolerance, or death. Interim analysis at
4 years showed significant improvement in TTP (42 months
in lenalidomide arm versus 27 months in the placebo arm;
𝑃 < 0.001).
A subgroup analysis showed that patients treated with
lenalidomide induction therapy had significantly longer sur-
vival if they received lenalidomidemaintenance, compared to
those who received a placebo. The same analysis also showed
that lenalidomide maintenance did not provide a survival
advantage for patients who were treated with thalidomide
induction therapy, patients who had elevated 𝛽-2 microglob-
ulin levels, or patients who achieved a CR prior to the start of
maintenance therapy or placebo.
Based on these results, the study was unblinded and 82
out of 128 patients in the placebo arm crossed over to the
lenalidomide maintenance arm. Dr. McCarthy updated the
results of CALGB-100104 trial in 2013 at the International
Myeloma Workshop in Japan. Intention-to-treat analysis
conducted at amedian follow-up of 48months after crossover
showed median TTP of 50 months in the lenalidomide
maintenance arm versus 27 months in the placebo arm. OS
benefit wasmaintained at 48months (medianOS not reached
in the lenalidomide maintenance arm versus 73 months in
the placebo group, 𝑃 = 0.008). Interestingly, OS analysis of
patients crossing over from placebo to lenalidomide within
6–12 months of randomization showed significant benefit
from lenalidomide maintenance [49].
The difference in survival results between the CALGB
and IFM trials may be due to differences in induction
consolidation and maintenance therapies.
In the IFM trial, one half got VAD and one quarter got
augmented with DICEP, 20% of patients got two transplants,
and maintenance was discontinued at a median of 32 months
from the start. Longer follow-up and additional studiesmight
clarify the differences in results.
Most recently, Palumbo et al. reported results of the open-
label, randomized, phase III study comparing melphalan
200mg/m2 followed by ASCT versusmelphalan-prednisone-
lenalidomide (MPR).This study also compared lenalidomide
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Figure 3: Meta-analysis of thalidomide maintenance showing OS
benefit (adapted from [15]).
maintenance to no maintenance after high-dose melpha-
lan or MPR consolidation. In comparison to no main-
tenance, lenalidomide maintenance significantly reduced
the risk of progression independently of previous induc-
tion/consolidation regimen (PFS 41.9 versus 21.6 months,
𝑃 < 0.001) with a trend towards improved 3-year OS rates in
the lenalidomide maintenance arm (88% versus 79.2%, 𝑃 =
0.14). Response rates improved during maintenance therapy
in both high-dose melphalan and MPR arms. Interestingly,
despite a similar CR rate, PFS improved in thosewho received
high-dose melphalan in comparison to MPR chemotherapy.
One possible explanation stated by authors is that response
was assessed with standard laboratory tests rather thanMRD
detection by immunophenotypic or molecular techniques
which may have revealed subtle differences in response
between the two groups [50]. The concept of PFS2, defined
as the time from initial randomization to time of objective
disease progression after next-line therapy or death from any
cause, was recently proposed as a surrogate toOS, particularly
in trials evaluating maintenance in MM. This is due to the
fact that effective salvage therapies are likely to be available at
relapse which is thought to be the main reason for the lack
of any statistically significant survival advantage noted across
the trials addressing this topic [51].
4.2.1. Second Primary Malignancies (SPMs) after Lenalido-
mide Maintenance. Enthusiasm for lenalidomide mainte-
nance after HDC-ASCT in MM was subdued by the concern
for increased risk of SPMs reported in both IFM and CALGB
trials. Interim analysis of IFM trial showed increased risk of
SPMs (3.1 versus 1.2 per 100 patients per year) in the lenalido-
mide maintenance arm [47]. Based on this, lenalidomide
maintenance was halted. CALGB trial reported risk of SPMs
of 12% in the maintenance versus 6% in the placebo arm
(𝑃 = 0.034) [29]. However, in the CALGB trial maintenance
was continued and, of notice, no new cases of SPMs were
reported with longer follow-up [49].
The incidence of SPMs following lenalidomide expo-
sure was reviewed in a recently published meta-analysis of
7 randomized trials including 2620 patients treated with
lenalidomide versus 598 patients treated with no lenalido-
mide exposure [52]. Risk of SPMs at 5 years was 6.9% versus
4.8% (HR 1.1; 95%CI 1.03–2.34) which was statistically signif-
icant for second primary hematologicmalignancies only.This
increased risk is thought to be driven by treatment strategies
combining lenalidomidewith oralmelphalan, suggesting that
alkylator-free alternatives might be a better combination
when using lenalidomide for myeloma patients.
On the other hand, acute myeloid leukemia (AML) and
myelodysplasia (MDS) were reported in high frequency
in untreated patients with monoclonal gammopathy of
undetermined significance (MGUS) [53]. This suggests that
hematopoietic stem cell or microenvironmental defect may
be leading to the increased risk of hematological malignan-
cies rather than the effect of chemotherapy exposure alone.
In conclusion, data with lenalidomide maintenance
after ASCT is favorable. However, the optimal duration
of lenalidomide maintenance is still unclear. Lenalidomide
provides the most benefit in those who fail to achieve CR or
very good partial response (VGPR), by IMWG criteria, after
ASCT.
4.3. Bortezomib Use after ASCT. The use of bortezomib
in the post-ASCT setting in myeloma was evaluated in
multiple randomized trials as consolidation, maintenance
and in combination with other agents [39, 54, 55]. In the
Nordic Myeloma Study Group trial, single-agent bortezomib
consolidation given as 20 doses after ASCT resulted in 7-
month improvement in PFS compared to placebo (𝑃 =
0.007); however, no OS benefit was seen. This approach
seemed to be most beneficial for patients achieving less than
a VGPR after induction and ASCT [54].
HOVON-65 trial evaluated bortezomib given during
induction and during maintenance in 827 newly diagnosed
myeloma patients [39]. Patients receiving bortezomib had
improved PFS compared to those who received nonborte-
zomib induction regimens (𝑃 = 0.006). There was a trend
towards improvement in 5-year OS survival rates (61% with
bortezomib regimens versus 55% in nonbortezomib arm)
but this did not reach statistical significance (𝑃 = 0.07).
Bortezomib maintenance significantly improved nCR/CR
rate from 31% to 49%, which was found, in a landmark
analysis, to be associated with better PFS and OS at 12
months. However, in this trial, no random assignment for
maintenance therapy was performed; and, therefore, the
effect of that cannot be independently assessed. Furthermore,
the major part of the difference in nCR/CR rates between the
two groups was observed after induction and ASCT favoring
the bortezomib arm. Equivalent upgrade of response was
noted with either bortezomib or thalidomide maintenance.
Nonetheless, maintenance treatment with bortezomib was
much better tolerated than thalidomide maintenance, with
fewer patients stopping treatment prematurely. Subgroup
analysis showed that the superior outcomes with bortezomib
were predominantly accomplished in patients with high-
risk disease and myeloma-related renal failure or those with
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Figure 4: Collective data from thalidomide trials favoring maintenance (adapted from [16]).
del(17p) and del(13q) [39]. In patients with increased serum
creatinine, bothmedian PFS (30 versus 13months,𝑃 = 0.004)
and OS (54 versus 21 months, 𝑃 < 0.001) were significantly
improved in the bortezomib-containing arm compared to
those who did not receive bortezomib. In patients with
normal serum creatinine, PFS remained superior in the
bortezomib arm, whereas OS was similar in both groups.
Patients with abnormal FISH results for del(13q14), t(4; 14),
and del(17p13) were compared with patients without the
abnormality. PFS was worse in all patients with del(13q14)
regardless of the treatment arm whereas OS in patient with
del(13q14)was similar to thosewho did not carry the deletion.
Of note, OS in patients with the deletion was significantly
better in the bortezomib arm in comparison to the nonborte-
zomib arm. In patients with del(17p13), both PFS (median 22
versus 12 months, 𝑃 = 0.01) and OS (median > 54 months
versus 24 months, 𝑃 = 0.003) were significantly better in
the bortezomib arm. The presence of t(4; 14) was associated
with worse outcomes compared to patients without this
translocation. There was a trend towards better outcomes in
patients with t(4; 14) who received bortezomib-containing
regimen; however, this did not reach statistical significance.
This leads us to the conclusion that the use of bortezomib in
the post-ASCT setting can potentially overcome the adverse
effects of abnormal cytogenetics, a subgroup that has always
been associated with inferior outcomes.
4.4. Combination Regimens after ASCT. Trials in the recent
years focused on combination regimens for consolida-
tion/maintenance after ASCT. The Spanish PETHEMA
study was a 3-arm randomized trial that evaluated borte-
zomib/thalidomide maintenance after ASCT versus single-
agent IFN or single-agent thalidomide for a period of 3
years [55]. After a median follow-up of 24 months from
maintenance initiation, PFS was significantly longer in borte-
zomib/thalidomide arm (78%) compared with thalidomide
arm (63%) or IFN arm (49%), with no relevant difference
in side effects except for higher incidence of neuropathy in
the combination arm. Interestingly, the improvement in PFS
was primarily seen in patients with low-risk cytogenetics,
contrary to what was reported by HOVON-65 trial. This
discrepancy might be in part due to different bortezomib
dosing and duration (52 doses over 2 years in HOVON-65
versus 48 doses over 3 years in PETHEMA trial).
Cavo et al. evaluated the combination bortezomib/thal-
idomide/dexamethasone (VTD) versus thalidomide/dexam-
ethasone (TD) as consolidation therapy after ASCT in 474
newly diagnosed myeloma patients [17]. After consolidation,
CR (60.6% versus 46.6%) and nCR (73.1% versus 60.9%)
rates were significantly higher for VTD arm versus TD
arm. Notably, VTD consolidation significantly increased
CR/nCR rates compared to pretransplant rates, whereas
TD did not. With a median follow-up of 30.4 months
from initiation of consolidation, 3-year PFS was significantly
longer for the VTD group versus TD group (60% versus
48%). Furthermore, PFS curves in the VTD arm were almost
superimposable regardless of the presence or absence of
cytogenetic abnormality, whereas patients who received TD
consolidation and carried abnormal cytogenetics had signifi-
cantly worse outcomes (Figure 5).
Total therapy (TT) trials are series of studies con-
ducted by the Arkansas Myeloma Group utilizing all active
antimyeloma agents upfront to achieve a maximal tumor
cytoreduction and thereby increase the frequency and dura-
tion of CR, with the goal of extending PFS and OS (see
Figure 6).
The introduction of bortezomib in the post-ASCT setting
started with TT-3A (VTD-PACE for 2 cycles as consolidation
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Figure 5: Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy according to the presence or absence of
cytogenetic abnormalities. The figure shows PFS for patients with no cytogenetic abnormality or with del(13q) positivity but lack of t(4;
14) and del(17p) or t(4; 14) and/or del(17p) positivity which received VTD consolidation therapy (a) or TD consolidation therapy (b). ∗𝑃
value according to log-rank test (adapted from [17]).
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Figure 6: It summarizes the series of Total therapy trials. VAD:
vincristine, doxorubicin, and dexamethasone; HD-Cyt: high-dose
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and cisplatin; TD-PACE: thalidomide, dexamethasone, cisplatin,
doxorubicin, cyclophosphamide, and etoposide; VTD: bortezomib,
thalidomide, and dexamethasone; VRD: bortezomib, lenalidomide,
and dexamethasone.
followed by either VTD for 1 year or TD for 2 years).
The upfront addition of bortezomib resulted in improved
outcomes, compared with TT-2 trials that randomized
patients upfront to receive/not receive thalidomide as part of
induction, consolidation, and maintenance. To validate these
findings along with bortezomib pharmacogenomic data, a
successor trial TT-3B enrolled another 177 patients. TT-3A
andTT-3Bwere identical in design, except for the fact that the
maintenance phase of TT-3B included VRD (using lenalido-
mide instead of thalidomide) and was continued for 3 years
rather than 1 year in TT-3A (Figure 6). Comparing results of
TT-3A and TT-3B, the difference between OS (87% in TT-
3B versus 85% in TT-3A) and EFS (83% in TT-3B versus 80%
in TT-3A) at 2 years was not statistically significant [56, 57].
When examined in the context of GEP-defined risk, TT-
3A and TT-3B result curves were superimposable for both
low-risk and high-risk groups. However, more patients with
GEP-defined high risk were included in TT-3B versus TT-3A
(22% versus 15%, 𝑃 = 0.038). Despite more adverse features
in TT-3B and overall higher-risk population, all outcomes
(OS, EFS, and CR duration) were similar in the 2 proto-
cols suggesting that 3-year maintenance with a bortezomib-
containing regimen is superior to shorter maintenance, along
with the reportedly more effective immunomodulatory effect
of lenalidomide compared to thalidomide used in TT-3A
[56–58]. Furthermore, according to multivariate analysis,
deletion TP53 conferred inferior OS and EFS in TT-2 but
not in TT-3. The major difference between TT-2 and TT-
3 is the addition of bortezomib in induction, consolidation,
and maintenance phases. This provides further evidence that
the use of proteasome inhibitors in all treatment phases can
potentially negate the adverse consequences of deletion TP53,
likely through a synergistic mechanism [59].
Most recently, Nooka et al. reported results of a single-
arm trial evaluating consolidation and maintenance therapy
with lenalidomide, bortezomib, and dexamethasone (RVD)
in patients with high-risk cytogenetics, defined as del TP53,
del(1p), t(4; 14), or t(14; 16). Patients received different
induction regimens followed by ASCT and subsequently
RVDmaintenance for 3 years followed by lenalidomide until
disease progression. Following initiation of RVD mainte-
nance, 51% of patients achieved sCR with 96% achieving at
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least VGPR as best response. Median PFS for all patients was
32 months and 3-year OS of 93% was reported [60].
Furthermore, in their recent phase II IFM study, Roussel
et al. reported high-quality response and favorable tolera-
bility. This phase II trial included 31 newly diagnosed MM
patients who were eligible for ASCT. Overall, 27% of patients
were classified as having high-risk chromosomal abnormali-
ties based on either having a del(17p) or t(4; 14) abnormality,
determined by FISH. Patients received three cycles of RVD
and then proceeded to ASCT. Two months after recovery of
blood counts, patients who had not progressed received con-
solidation therapy consisting of two cycles of RVD. Patient
subsequently received maintenance therapy with continuous
lenalidomide (Revlimid) for one year. Responses deepened
significantly after ASCT and consolidation therapy in com-
parison to responses at the end of induction: 40% reaching
sCR versus 10%; 58% of patients were MRD-negative versus
16%. Responses also improved further for some patients
during maintenance therapy. After all treatment sequences,
68% of patients had achieved MRD negativity. At a median
follow-up of 39 months, the estimated 3-year PFS and OS
were 77% and 100%, respectively [61]. None of the patients
who had achieved MRD negativity relapsed within three
years of diagnosis. Of note, PFS was significantly lower at
23% in patients who had never reached MRD negativity. The
most common side effect during lenalidomide maintenance
therapy was low blood cell counts.
4.5. Maintenance Using Immunotherapeutics and Future
Modalities. Dendritic cell vaccination, an example of this
approach, works by induction of idiotype-specific T- and
B-cell response that can stimulate the body’s own immune
system to fight and eradicate myeloma cells following admin-
istration of idiotype-protein pulsed dendritic cells. Although
this seems to be a safe strategy, it has not shown any effects
on survival and, to date, remains experimental [62–64].
Other forms of immunotherapy include the monoclonal
antibody Elotuzumab (anti-CS1) and Daratumumab (anti-
CD38) that have activity both as single agents and in com-
bination with other novel therapeutics. Novel proteasome
inhibitors such as Carfilzomib, Marizomib, Ixazomib, and
Oprozomib may provide better outcomes in the future.
Antibodies to various myeloma cell markers, such as CD40,
CD56, CD74, IL-6, TRAIL, and RANKL, combined with
proteasome inhibitors, conventional chemotherapy, and/or
immunomodulatory agents, may serve as maintenance tar-
gets for future research with an ultimate goal of significantly
improving OS or potentially curing multiple myeloma [27,
65].
5. Summary and Recommendations
Over the last decade, the trials mentioned above have led
to markedly improved outcomes in myeloma and answered
multiple questions regarding optimal induction regimens as
well as highlighting the importance of consolidation/mainte-
nance after ASCT in the era of novel agents. While consider-
ing consolidation/maintenance strategies after HDC-ASCT,
one needs to take into careful consideration the cost and
toxicity involved with the different strategies in order to
improve outcomes. The use of sensitive techniques to detect
MRD provides a stratification tool to guide further treatment
following ASCT.
Patients with low-risk disease and normal cytogenetics,
who achieve CR or sCR (per IMWG criteria) after ASCT,
especially if this excellent response can be confirmed by
MRDnegativity, may forgo further therapy after ASCT.These
patients will need to be closely followed for evidence of
relapse. Patients with high-risk cytogenetics and those with
low-/standard-risk cytogenetics who achieve less than a CR
should be considered for maintenance treatment. Average
time to start consolidation/maintenance is typically 60–100
days after ASCT.
Nooka et al. have reported excellent outcomes for patients
with high-risk cytogenetics using combination RVD followed
by lenalidomide maintenance. However, this needs further
validation in a phase II/III trial design to confirm these
superior results. Roussel regimen (2 cycles of RVD followed
by lenalidomide maintenance) is promising particularly in
the setting of less than a CR with HDC-ASCT.
Our institutional approach for high-risk cytogenetics and
low-/standard-risk cytogenetic patients who are still MRD
positive after HDC-ASCT is an approach similar to Roussel
regimen’s with continuation of RVD beyond 2 cycles until
achievement of MRD negativity followed by lenalidomide
maintenance as long as tolerated or until progression.
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